Journals / Jinekoloji Obstetrik Pediatri ve Pediatrik Cerrahi Dergisi / 2012 / Cilt: 4 - Sayı: 1

The Effects of addition of GnRH antagonist in infertile patients who were treated with gonadotrophin

İnfertil hastalarda gonadotropin ile ovulasyon indüksiyon protokolüne, gonadotropin realising hormon antagonisti ilavesinin etkileri

Pages
1–9
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Adding GnRH antagonist in cycles with rFSH followed by IUI has significant effect on early LH surge, but it does not increase pregnancy rates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to invastigate the cycle outcomes and pregnancy rates in infertile patients treated with GnRH antagonist added gonadotrophins followed by intrauterin insemination (IUI).
📊
Key Findings & Data:Materials and Methods: This is a randomised controlled trial starting from may 2010 to may 2011, with the verdiction of Health Ministery Bakırkoy Gynecology and Obstetrics and Pediatrics Education and Research Hospital Ethics Commitee dated 12/06/2009 and numbered 254.
💡
Conclusion & Impact:Conclusion: Adding GnRH antagonist in cycles with rFSH followed by IUI has significant effect on early LH surge, but it does not increase pregnancy rates.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to invastigate the cycle outcomes and pregnancy rates in infertile patients treated with GnRH antagonist added gonadotrophins followed by intrauterin insemination (IUI). Materials and Methods: This is a randomised controlled trial starting from may 2010 to may 2011, with the verdiction of Health Ministery Bakırkoy Gynecology and Obstetrics and Pediatrics Education and Research Hospital Ethics Commitee dated 12/06/2009 and numbered 254. We analysed the data on IUI cycles starting from may 2010 to may 2011 in 56 cycles of 47 patients diagnosed with unexplained infertility and polycyctic ovary syndrome (PCOS) with current guidelines (RCOG and Rotterdam Concensus 2003). All patients were treated with recombinant FSH in a low dose step up regimen starting on day 2-4. 25 women in the antagonist group, 0,25 mg per day GnRH antagonist was added when leading follicul reached the size of 14 mm in 30 cycles. In the control group there were 22 women treated with only recombinant FSH in 26 cycles. When at least one follicle reached a size of ≥18 mm, ovulation was induced by hCG injection. IUI was performed 36 hours later. Results: rFSH amount, number of follicules, E2 level in the hCG day and endometrial thickness were not significantly different between the antagonist group and the control group. Also there was statistically no difference in the induction period time. Mean early LH peak was observed in %3.3 of cases of antagonist group, while it was %34.6 in the control group, showing that the early LH peak was statistically lower in the antagonist group (p:0.002) but there was no statistical difference in the pregnancy rate for cycle between the two groups, as %10 in the antagonist and %7.7 in the control group (p:0.763). Conclusion: Adding GnRH antagonist in cycles with rFSH followed by IUI has significant effect on early LH surge, but it does not increase pregnancy rates.

Özet

Amaç: Kontrollü overyan stimulasyon ve intrauterin inseminasyon planlanan hastalarda, ovulasyon indüksiyon protokolüne gonadotropin realising hormaon antagonisti (GnRHant) ilavesinin siklus ve gebelik oranları üzerine etkisinin araştırılması. Materyal ve Metod: Çalışmamız randomize kontrollü çalışma olup Mayıs 2010 ile mayıs 2011 tarihleri arasında Sağlık Bakanlığı Bakırköy Kadın Doğum ve Çocuk Hastalıkları Eğitim Araştırma Hastanesi Etik Kurulunun 12.06.2009 tarihli ve 254 sayılı kararı ile başlatılmıştır. Güncel verilere ve tanı kriterlerine dayanılarak (RCOG-Rotterdam 2003) açıklanamayan infertilite ve polikistik over sendromu (PKOS) tanısı alan 47 hastada 56 siklus incelenerek çalışma yapıldı. Tüm hastalara siklusun 2-4. gününde düşük doz step up protokolüne göre rFSH ile ovulasyon indüksiyonu ile tedaviye başlandı. Antagonist grubunda 25 hastaya 30 siklusda rFSH’a, önde giden folikül çapı 14 mm’ye ulaştığında tedaviye 0.25 mg/gün GnRHant eklendi. Kontrol grubunda 22 hastaya 26 siklusda yalnızca rFSH kullanılarak düşük doz step-up protokolü ile ovulasyon indüksiyonu sonrası önde giden folikül 18 mm’ye ulaştığında 250 mcg rekombinant hCG enjeksiyonu yapıldı ve bundan 36 saat sonra İUİ uygulandı. Bulgular: İndüksiyon gün süresi, kullanılan ortalama rFSH miktarı (IU), folikül sayısı, hCG günü E2 düzeyi ve endometrial kalınlık açısından iki grup arasında istatistiksel olarak anlamlı bir farklılık gözlenmedi. Antagonist ilave edilen grupta erken LH piki % 3.3 ve kontrol grubunda % 34.6 saptanmış olup antagonist grubunda erken LH piki anlamlı olarak (P 0.002) daha az görüldü. Siklus başına gebelik oranları, antagonist grubunda % 10 ve kontrol grubunda %7.7 olup iki grup arasında istatiksel olarak anlamlı fark bulunmadı (P 0.763). Sonuç: Gonadotropinlerle yapılan ovulasyon indüksiyon protokolüne GnRHant eklemenin, erken LH pikini anlamlı olarak azalttığı ama gebelik sonuçları üzerine bir etkisi olmadığı görülmüştür.

🔖

Cite This Article

TEKİRDAĞ, A. İ., ÜLKER, V., YILDIRIM, G., HASBAJRAMI, A., BAKIR, V. L., ALKIŞ, İ., POLAT, İ. (2022). The Effects of addition of GnRH antagonist in infertile patients who were treated with gonadotrophin. Jinekoloji Obstetrik Pediatri ve Pediatrik Cerrahi Dergisi, Cilt: 4 - Sayı: 1, 1–9. https://ajindex.com/articles/558563

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. M M atorras R, Diaz T, Corkostegui B, Ramón O, Pijoan JI, Rodriguez-Escudero FJ. Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSH. Hum Reprod 2002
  2. 17(8): 2107-11. http://dx.doi.org/10.1093/humrep/17.8.2107 PMid:12151445 2. ESHRE Capri Workshop Group. Intrauterin insemination. Hum Reprod Update 2009
  3. 15(3): 265-77. http://dx.doi.org/10.1093/humupd/dmp003 PMid:19240042 3. Dickey RPA year of inaction on high-order multiple pregnancies due to ovulation induction. Fertil Steril 2003
  4. 79(1):14-6. http://dx.doi.org/10.1016/S0015-0282(02)04561-2 4. M M atikainen T, Ding YQ, Vergara M, Huhtaniemi I, Cuuzinet B, Schaison G. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol Metab 1992
  5. http://dx.doi.org/10.1210/jc.75.3.820 5. Olivennes F, Cunha-Filho JS JS, Fanchin R, Bouchard P, Frydman R. The use of GnRHants in ovarian stimulation. Hum Reprod Update 2002
  6. http://dx.doi.org/10.1093/humupd/8.3.279 PMid:12078838 6. Felberbaum RE, Albano C, Ludwig M, Riethmuller-Winzen H, Grigat M, Devroey P, Diedrich K. Ovarian stimulation for assisted reroduction with hMG and concomitant midcycle administration of the GnRHant cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000
  7. http://dx.doi.org/10.1093/humrep/15.5.1015 PMid:10783344 7. Garcia-Velasco JA, Isaza V, Vdal C, et al. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod 2001
  8. 16(12):2533-9. http://dx.doi.org/10.1093/humrep/16.12.2533 PMid:11726570 8. Williams RS, Hillard JB, De Vane G, Yeko T, Kipersztok S, Rhoton-Vlasak A, Sistrom C. A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy. Am J Obstet Gynecol 2004
  9. 191(2):648-51. http://dx.doi.org/10.1016/j.ajog.2004.06.072 PMid:15343256 9. L L ambalk CB, Leader A, Olivennes F, Fluker MR, Andersen AN, Ingerslev J, Khalaf Y, et al. Treatment with the GnRHant ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod 2006
  10. 21(3):632-9. http://dx.doi.org/10.1093/humrep/dei386 PMid:16361296 10. Crosignani PG, Som